Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function

Highlights
- Chronic viral infection causes long-term transcriptome and proteome changes in the liver
- Hepatocyte-intrinsic type I interferon (IFN-I) signaling regulates hepatic metabolism
- IFN-I signaling reprograms the urea cycle in hepatocytes and alters serum metabolites
- Serum levels of arginine and ornithine modulate T cell responses and pathology

In Brief
The liver is a central regulator of metabolism, but how infection-induced changes in liver metabolism affect immune responses and pathology remains enigmatic. Lercher et al. demonstrate that hepatocyte-intrinsic type I interferon (IFN-I) represses metabolism during chronic viral infection. Specifically, IFN-I disrupts the urea cycle in hepatocytes, altering serum arginine and ornithine levels, which dampen antiviral T cells responses and liver pathology.
Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function

Alexander Lercher,1,14 Anannya Bhattacharya,1,13,14 Alexandra M. Popa,1 Michael Caldera,1 Moritz F. Schlapansky,1 Hatooon Baazim,1 Benedikt Agerer,1 Bettina Gurtl,1 Lindsay Kosack,1 Peter Májek,1 Julia S. Brunner,2,23 Dijana Vitko,1,4 Theresa Pinter,1,12 Jakob-Wendelin Genger,1 Anna Orlova,6 Natalia Pikor,7 Daniela Reil,1 Maria Oszvár-Kozma,1,6 Ulrich Kalinke,9 Burkhard Ludewig,7 Richard Moriggl,5,10 Keiryn L. Bennett,1 Jörg Menche,1 Paul N. Cheng,11 Gernot Schabauer,2,23 Michael Trauner,12 Kristaps Klavins,1 and Andreas Bergthaler1,15,*

1CeMM Research Center for Molecular Medicine or the Austrian Academy of Sciences, Lazarettgasse 14 AKH BT25.3, 1090 Vienna, Austria
2Department of Thrombosis Research and Vascular Biology, Medical University of Vienna, 1090 Vienna, Austria
3Christian Doppler Laboratory for Arginine Metabolism in Rheumatoid Arthritis and Multiple Sclerosis, 1090 Vienna, Austria
4Department of Urology, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
5Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), 1030 Vienna, Austria
6Division of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
7Institute of Immunobiology, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland
8Department for Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria
9Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Helmholtz Centre for Infection Research, Braunschweig, and the Hannover Medical School, 30625 Hannover, Germany
10Medical University of Vienna, 1090 Vienna, Austria
11Bio-Cancer Treatment International Limited, Hong Kong, China
12Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria
13Present address: Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115, USA
14These authors contributed equally
15Lead Contact
*Correspondence: aberghthaler@cemm.oeaw.ac.at
https://doi.org/10.1016/j.immuni.2019.10.014

SUMMARY

Infections induce complex host responses linked to antiviral defense, inflammation, and tissue damage and repair. We hypothesized that the liver, as a central metabolic hub, may orchestrate systemic metabolic changes during infection. We infected mice with chronic lymphocytic choriomeningitis virus (LCMV), performed RNA sequencing and proteomics of liver tissue, and integrated these data with serum metabolomics at different infection phases. Widespread reprogramming of liver metabolism occurred early after infection, correlating with type I interferon (IFN-I) responses. Viral infection induced metabolic alterations of the liver that depended on the interferon alpha/beta receptor (IFNAR1). Hepatocyte-intrinsic IFNAR1 repressed the transcription of metabolic genes, including Otc and Ass1, which encode urea cycle enzymes. This led to decreased arginine and increased ornithine concentrations in the circulation, resulting in suppressed virus-specific CD8+ T cell responses and ameliorated liver pathology. These findings establish IFN-I-induced modulation of hepatic metabolism and the urea cycle as an endogenous mechanism of immunoregulation.

INTRODUCTION

Pathogens and concurrent tissue damage elicit complex context-dependent inflammatory response programs (Hotamisligil, 2017). Chronic infections represent a particular challenge for the host organism, which is exposed to prolonged inflammation that may predispose to various co-morbidities, such as susceptibility to secondary infections and cancer (Okin and Medzhitov, 2012; Rehermann and Nascimbeni, 2005; Virgin et al., 2009). The same inflammatory pathways can also control cellular tissue homeostasis and metabolism (Kotas and Medzhitov, 2015; Medzhitov, 2008). The liver is a central metabolic organ but also represents an immunoregulatory hub between blood-borne pathogens and the immune system (Jenne and Kubes, 2013; Protzer et al., 2012; Racanelli and Rehermann, 2006). Hepatocytes are the functional unit of the liver parenchyma and the most abundant cell type of the liver. As such, their principal task is the turnover of metabolites during homeostasis. Yet they are also important immune signaling platforms that produce and react to a range of cytokines upon inflammation (Crispe, 2016; Racanelli and Rehermann, 2006; Zhou et al., 2016). Hepatocytes themselves are permissible to a variety of chronic viruses, including hepatitis B virus (HBV) and hepatitis C virus (HCV) in humans and lymphocytic choriomeningitis virus (LCMV) in...
mice (Guidotti et al., 1999; Rehermann and Nascimbeni, 2005). The chronic infection model of LCMV represents a well-established and pathophysiologically relevant experimental model for the study of host-pathogen interactions and immune responses that induce a vigorous CD8 T-cell-dependent hepatitis (Zehn and Wherry, 2015; Zinkernagel et al., 1986). The involved immunopathologic mechanisms seen in the LCMV model are similar to those observed in patients chronically infected with HBV or HCV (Guidotti et al., 1999; Rehermann and Nascimbeni, 2005).

Soluble inflammatory signals act mainly through cytokine receptors (Hotamisligil, 2017; Protzer et al., 2012; Racanelli and Rehermann, 2006). Type I interferons (IFN-Is) are central antiviral cytokines that signal through the ubiquitously expressed IFNAR receptor, which is composed of the two subunits IFNAR1 and IFNAR2. This induces the expression of a broad array of genes described as interferon-stimulated genes (ISGs). ISGs exert antiviral functions by direct interference with viral replication and immunoregulatory properties (McNab et al., 2015; Schoggins et al., 2011). More recently, IFN-Is are also recognized as modulators of metabolism, such as cellular lipid metabolism and redox homeostasis (Bhattacharya et al., 2015; Pantel et al., 2014; Wu et al., 2016; York et al., 2015). Cytokine-induced regulation of liver metabolism is expected to result in altered metabolite turnover and release that impacts distal organs (van den Berghe, 1991; Norata et al., 2015). Immune cells and in particular T cells critically depend on certain metabolites to efficiently perform their functions and are thus susceptible to altered metabolite availability (Chang et al., 2015; Geiger et al., 2016; Johnson et al., 2018; Pearce et al., 2009). In line with this, a frequent immune evasion mechanism of cancer is the depletion of essential amino acids or glucose in the tumor microenvironment (Buck et al., 2017; Chang et al., 2015; Ma et al., 2017; Murray, 2016).

In this study, we investigated the chronic infection model of LCMV using an unbiased integrative approach to unveil inflammation-driven endogenous regulation of liver metabolism and its impact on systemic immune responses and tissue pathology.

RESULTS

Identification of Inflammatory-Metabolic Changes in the Liver during Chronic Infection

We infected C57BL/6J wild-type mice with $2 \times 10^6$ focus forming units (FFUs) of the chronic strain clone 13 of LCMV and quantified infectious virus particles and viral RNA in the liver (Figure 1A). This confirmed the peak of viral propagation around day 8 after infection with a subsequent decline of viral loads. Liver damage was assessed by the clinical hallmark parameters alanine aminotransferase (ALT) and aspartate aminotransferase (AST) that peaked on day 8–12 after infection (Figure 1B). In an unbiased approach to virus-induced changes in the liver, we collected liver tissue from infected mice at different phases of infection (day 2 = innate phase; day 8 = peak of disease; day 30 = chronic phase; day 60 = resolving phase) and performed transcriptome analyses by RNA sequencing (RNA-seq). The transcriptomic data showed high intra-replica reproducibility and individual samples clustered according to the time course of infection (Figure 1C), highlighting phase-specific changes in gene expression and the gradual recovery of mice by 60 days after infection. In total, 3,626 transcripts were differentially regulated (Table S1A) and the most differentially expressed genes were found on days 2 and 8 after infection (Figure 1A). Hierarchical clustering identified three broad categories of gene expression programs, including transcripts that were found already regulated on day 2 (clusters 1–4) or induced on day 8 (clusters 5–10) as well as transcripts that were repressed during infection (clusters 11–15; Figure 1D; Table S2A). To corroborate transcriptional alterations, we performed tissue proteomics and quantified 5,586 proteins in the liver (Table S1B). Protein changes correlated with differentially expressed transcripts (Figures 1E and S1B; Table S2C). Of the identified clusters, differentially expressed genes associated with antiviral IFN-I signaling were found to be enriched on day 2 (clusters 1–4; Figure 1F; Table S2B) although leukocyte-associated genes were mainly found on day 8 after infection (clusters 5–10; Figure 1F; Table S2B). Some of these differential expression changes are likely to reflect hepatic immune cell infiltration (Figure S1C).

Our enrichment analyses indicated widespread metabolic reprogramming of liver tissue during LCMV infection (Figure S1D), with particularly pronounced effects seen for downregulated metabolic pathways relating to lipid and amino acid metabolism on days 2 and 8 after infection (clusters 11–15; Figure 1F; Table S2B). This is in line with our recent study about the modulation of circulating lipids during acute LCMV infection (Kosack et al., 2017). For an in-depth integration of these metabolic changes, we performed enrichment analyses of the union of differentially regulated transcripts and proteins at each stage of viral infection on Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathways. We identified global reprogramming of processes related to all the major classes of metabolites. Modulation of hepatic pathways involving lipids and essential amino acids was initiated on day 2 and peaking on day 8 after infection.
Differentially expressed metabolic processes were also found in the chronic and resolving phases of infection, although the number of modulated transcripts and proteins were lower (Figures 1G, S1A, and S1B).

To address the effects of virus-induced alterations on the metabolic output of the liver, we performed targeted metabolomics of serum, focusing on amino acids, biogenic amines, sphingolipids, acylcarnitines, and glycerophospholipids. We found 99 of 180 metabolites to be significantly regulated at one or more time points (Figure 1H; Table S3A). Downregulation of metabolites on day 2 (Figure S1E) was observed for glycerophospholipids and amino-acid-related metabolic pathways on day 8 (Figures 1F–1H; clusters 1 and 3) although acylcarnitines (Figure 1H; cluster 4) were rather upregulated on day 8 after infection (Figure 1H). Systemic amino acids and biogenic amines exhibited a sustained decline from day 2 to day 8 and gradually recovered in the later phases of infection (Figure 1H; cluster 2). This affected almost exclusively essential and semi-essential proteinogenic amino acids (His, Ile, Leu, Met, Trp, Val, and Arg; Figure 1H) and coincided with transcriptional regulation of amino-acid-related metabolic pathways on day 8 (Figures 1F–1H and S1F; Table S1C). Together, our integrated transcriptomic and proteomic analysis linked changes in the liver with altered systemic metabolite levels during chronic viral infection.

**Reduced Food Intake during Viral Infection Mildly Affects Gene Expression in the Liver**

Mice infected with LCMV strain clone 13 develop infection-associated cachexia (Baazim et al., 2019) and display reduced food intake (Figure S2A). We therefore performed a pair-feeding experiment to investigate the impact of infection-associated changes in food uptake to the metabolic reprogramming of the liver 8 days after infection. Uninfected mice received restricted amounts of food equivalent to the amounts consumed by infected mice. Subsequently, we collected liver tissue of infected, pair-fed, and naive animals and performed transcriptome analyses. These results indicated that most of the observed transcriptional changes were linked to viral infection and independent of anorexic behavior (Figures 2A, S2B, and S2C). Uninfected pair-fed mice showed only minor differential gene expression changes that pertained mainly to lipid metabolism (Figures 2B and 2C; Table S4). Together, these experiments demonstrated that the majority of the observed virus-induced metabolic changes in the liver, including amino-acid-related pathways, correlated with the infection status of the mice and were independent of altered food intake (Figures 1H and 2D).

**IFN-I Signaling Reprograms Hepatic Metabolism**

The observed changes of hepatic amino acid metabolism became noticeable as early as 2 days, which coincides with peak serum levels of IFN-α and IFN-β in mice infected with LCMV (Bhattacharya et al., 2015). Thus, we aimed to dissect a potential role of early IFN-I signaling in the observed changes in the liver. To measure the impact of IFN-I signaling on liver parenchyma, we performed an extracellular metabolic flux analysis of primary murine hepatocytes upon stimulation with IFN-β in vitro. IFN-β affected proxies for mitochondrial respiration and glycolysis in an IFNAR1-dependent manner (Figures 3A and 3B), indicating that IFN-I signaling affects metabolism of hepatocytes. To deconvolute tissue heterogeneity in vivo and to assess the contribution of IFN-I signaling to metabolic reprogramming in the liver, we took advantage of a genetic model of hepatocyte-specific ablation of Ifnar1 (Alb-Cre ERT2 Ifnar1fl/fl [Ifnar1 Δ/Δ]) and respective littermate controls (Alb-Cre ERT2 Ifnar1 Δ/Δ [Ifnar1 Δ/Δ]). These mice did not reveal any genotype-specific differences in viremia or serum concentration of IFN-α 1.5 days after infection (Figures S3A–S3C), suggesting that any potential differences seen in expression profiling of liver tissue from Ifnar1 Δ/Δ versus Ifnar1 Δ/Δ mice is unlikely to be due to altered viral loads and/or systemic IFN-I responses. Moreover, naive and infected Ifnar1 Δ/Δ versus Ifnar1 Δ/Δ animals displayed comparable abundances of immune-cell-related transcripts, suggesting only minor differences of immune cell infiltration between the genotypes at this early time point after infection (Figure S3D). Next, we analyzed transcriptomic changes of liver tissue taken from uninfected and infected mice of either genotype at the peak of serum IFN-α levels and employed a limma (2 × 2 factorial) interaction model. This resulted in a set of 526 hepatocyte-intrinsic IFNAR1-regulated genes, which were found to be associated with both classical ISG responses as well as metabolic processes (Figures 3C, 3D, and S3E; Table S5A). The regulated genes could be divided into two major classes—IFNAR1-stimulated (cluster 1) and IFNAR1-repressed (cluster 2) genes (Figure 3C; Table S5B). The majority of induced genes were well-known classical ISGs encoding for antiviral effectors (cluster 1; Figure 3D; Table S5C; Schoggins et al., 2011). Interferon-repressed genes (IRGs), which are not that well characterized (Mostafavi et al., 2016; Schoggins et al., 2011), were found to be strongly enriched for metabolism-associated processes (cluster 2; Figure 3D; Table S5C). In addition, clusters 3 and 4 contained genes whose maintained expression depended on intact IFNAR1 signaling and were also associated with metabolic processes (Figure 3D; Table S5C). Hepatocyte-intrinsic IFNAR1 signaling mainly regulated metabolic genes on day 2 after infection. Notably, a bioinformatic intersection with our longitudinal data obtained from chronically infected wild-type mice suggested that the IFN-I-dependent regulation of many of these genes is maintained beyond these early time points (Figure 3E). Specifically, virus-induced gene regulation of amino-acid-related pathways (Figure 1) was driven by hepatocyte-intrinsic IFNAR1 signaling (Figure 3E) and corresponded with the differentially regulated metabolites observed in infected wild-type mice (Figure 1H). To investigate whether these metabolic changes depended on hepatocyte-intrinsic IFNAR1 signaling, we performed metabolomics and found that systemic serum levels were indeed regulated by local IFNAR1 signaling of hepatocytes (Figure S3F). In a more stringent analysis using the limma (2 × 2 factorial) interaction model, we found 15 serum metabolites to be regulated by hepatocyte-intrinsic IFNAR1 signaling, including the semi-essential amino acid arginine and its downstream metabolite ornithine (Figure 3F). In summary, our data indicate that hepatocyte-intrinsic IFNAR1 signaling acts as a transcriptional regulator of liver metabolism and results in changes of circulating metabolites during infection.

**Hepatocyte-Intrinsic Ifnar1 Signaling Breaks the Urea Cycle**

Arginine and ornithine are both key metabolites of the urea cycle. The involved enzymes are encoded by Arg1, Otc, and...
Ass1, which are primarily expressed in the liver, as well as Asl, which is ubiquitously expressed (Uhlen et al., 2015). Expression analysis of liver tissue of uninfected and infected Ifnar1<sup>D</sup>/D and Ifnar1<sup>+/+</sup> mice highlighted that expression of Otc and Ass1 was repressed in a hepatocyte-intrinsic IFNAR1-dependent manner (Figures 4A, S4A, and S4B). Arg1 was induced, whereas Asl was repressed upon infection, both independent of hepatocyte-intrinsic IFNAR1 signaling (Figure 4A). These infection-induced transcriptional changes of the urea cycle genes Otc, Ass1, Asl, and Arg1 were maintained on transcriptomic and proteomic level up to 30 days after infection, with the most pronounced effects seen on days 2 and 8 (Figures S4C–S4F). Of note, the regulation of Otc and Ass1 was independent of food intake (Figure S4G).

To corroborate the hepatocyte-specific origin of the observed reprogramming of the hepatic urea cycle, we performed single-cell RNA-seq (scRNA-seq) of primary murine hepatocytes isolated from naive or LCMV-infected wild-type mice 2 days after infection. Both samples showed comparable numbers of reads (uninfected: 1,493.5; infected: 1,429.0) and genes (uninfected: 705.5; infected: 761.0) per cell. We identified 348 differentially expressed genes in hepatocytes that correlated well with changes observed in bulk liver tissue (Figures 1, S4H, and S4I). Accordingly, genes induced in hepatocytes were associated with antiviral innate immune responses, whereas repressed genes were vastly associated with metabolic processes (Figures S4J and S4K). Hepatocytes clustered by the infection status of the mice (Figure 4B), and we confirmed hepatocyte-intrinsic repression of Ass1 and Otc upon infection, which inversely correlated with expression levels of the ISG Ifit1 on the single-cell level (Figures 4C and 4D). Transcriptional repression of Otc and Ass1 manifested in reduced abundance of OTC and ASS1 proteins in hepatocytes as observed by immunohistochemistry on days 2 and 8 after infection (Figures 4E and 4F). As expected, STAT1, a master regulator of IFNAR1 downstream signaling, was significantly upregulated in hepatocytes (Figures 4E and 4F). The modulation of

![Figure 2. Reduced Food Intake upon LCMV Infection Mainly Affects Lipid-Metabolism-Associated Genes in the Liver](image)

For (A)–(C), transcriptomic data are derived from one experiment. See also Figure S2.
Otc and Ass1 on day 2 and day 8 after infection was confirmed by real-time PCR in sorted hepatocytes (Figure 4G).

In line with this, liver tissue of infected mice exhibited reduced enzymatic activity of OTC and ASS1, which we measured by the abundance of the 13C-labeled reaction products argininosuccinate (ASS1) or citrulline (OTC) after pulsing with 13C-labeled substrates. Addition of the ASS1-specific inhibitor α-methyl-DL-aspartic acid (MDLA) abolished production of argininosuccinate and indicated specificity of the assay (Figure S4 L). In line with the IFNAR1-dependent increase of systemic ornithine levels upon infection (Figure 4A), these data indicate that IFNAR1 represses the degradation of ornithine via OTC in hepatocytes.

**Figure 3. Hepatocyte-Intrinsic IFNAR1 Signaling Is a Transcriptional Regulator of Liver Metabolism and Shapes Systemic Metabolism**

(A and B) Oxygen consumption rate (OCR) (A) and extracellular acidification rate (ECAR) (B) of wild-type and Ifnar1<sup>−/−</sup> primary hepatocytes treated for 4 h with IFN-β (n = 11).

(C) Clustering by expression profile (FPKM; k-means; Pearson's correlation) of transcripts significantly regulated (limma interaction model) by hepatocyte-intrinsic IFNAR1 signaling (n = 3).

(D) Enriched GO terms and pathways (ClueGO) of transcripts identified in the groups clusters in (C).

(E) Metabolism-associated transcripts significantly regulated by hepatocyte-intrinsic IFNAR1 signaling super-imposed on the previously identified significantly regulated metabolic transcripts and proteins at the indicated time points after LCMV infection (based on Figure 1G).

(F) Serum metabolites significantly regulated (limma interaction model) by hepatocyte-intrinsic IFNAR1 signaling in naive and LCMV-infected animals (n = 3). For (A) and (B), data for one out of two representative experiments are shown. For (C), (D), and (F), transcriptomic and metabolomic data are derived from one experiment. Symbols represent the arithmetic mean ± SEM; *p < 0.05; **p < 0.01 (Student’s t test). See also Figure S3.
The downregulation of Asl expression, together with decreased argininosuccinate, is expected to aggravate the infection-induced break in the urea cycle by limiting arginine re-synthesis (Figure 4A).

We confirmed the aforementioned transcriptional changes of the urea cycle and upregulation of Ifit1 in the viral infection model of coronavirus mouse hepatitis virus (MHV) by real-time PCR (Figure S4M). To test whether similar responses in the liver are seen in an inflammatory context, we administered the synthetic viral RNA analog and TLR3 agonist polyinosinic-polycytidylic acid (poly(I:C)) intraperitoneally to wild-type mice. Poly(I:C) treatment resulted in strong induction of Ifit1 and corroborated the upregulation of Arg1 and downregulation of Otc and Ass1 in liver tissue by real-time PCR (Figure S4N).

Treatment with 100 ng recombinant IFN-γ induced an ISG signature in the liver but did not yield reproducible changes of expression of these genes (data not shown), suggesting that interferon signaling is required, but not sufficient to regulate the urea cycle.

Next, we aimed to address whether viral infection leads to hyperammonemia, a hallmark parameter of urea cycle deficiency (UCD). Indeed, blood ammonia levels were significantly increased from 2 up to 8 days after LCMV infection, correlating with downregulation of the ammonia-fixating enzyme Cps1 (Figures 5A and S5A). This prompted us to further characterize the observed urea-cycle-related metabolic changes on a systemic level by in vivo tracing of $^{13}$C$_6$ heavy-isotope-labeled arginine (Figure 5B). Liver tissue of infected mice that received a bolus of $^{13}$C$_6$ arginine showed increased concentration of labeled ornithine and citrulline (Figure 5C). Arginine was not detected in the liver as reported previously (Wu et al., 2009). These local metabolic changes in the liver tissue, together with transcriptomic and proteomic changes in hepatocytes highly correlated with changes in systemic metabolism. We detected increased $^{13}$C$_6$ arginine degradation in the serum (Figure 5D), which is consistent with the induction of Arg1 (Figures 4A and S4C). Together with IFNAR1-dependent repression of Otc and Ass1 (Figures 4A–4D), this resulted in the systemic accumulation of $^{13}$C$_6$ ornithine and $^{13}$C$_6$ citrulline, respectively (Figure 5D). In accordance with increased arginine degradation and decreased ornithine degradation, we detected elevated levels of $^{13}$C$_1$-labeled urea in liver tissue (Figure S5B), whereas $^{13}$C$_1$-labeled urea was only mildly elevated in the circulation (Figure S5C). Together with the reduction of $^{13}$C$_6$ arginine, the end product of this pathway, these results support the notion that viral infection initiates a break of the hepatic urea cycle as early as 2 days after infection that persists at least until 8 days after infection and alters levels of metabolites in the circulation (Figure S5D).

Consistently, we observed a significant decrease of the arginine-to-ornithine ratio in the serum of mice infected with LCMV as a result of both reduced arginine and increased ornithine levels (Figures 5E and S5E). Similar changes in serum concentration of arginine and ornithine were seen upon infection with MHV (Figures S5F and S5G). Taken altogether, our results derived from different experimental models demonstrate conserved transcriptional and metabolic modulation of the urea cycle upon viral infection.

**Systemic Arginine-Ornithine Homeostasis Is a Regulator of Antiviral Adaptive Immunity**

Because activated T cells are auxotrophic for arginine (Geiger et al., 2016; Murray, 2016), we hypothesized that an altered arginine-to-ornithine serum ratio might exert immunomodulatory function. To test this in vitro, primary naive murine splenic CD8$^+$ T cells were activated with anti-CD3/CD28 antibodies for 3 days and IFN-γ and tumor necrosis factor alpha (TNF-α) production was assessed by flow cytometry. CD8$^+$ T cells cultured in medium with 11.5 μM arginine, a concentration comparable to the observed changes in vivo, displayed reduced cytokine production compared to standard cell culture medium containing 1,150 μM arginine (Figure 6A). Addition of ornithine, which is absent in standard cell culture medium, resulted in an additive suppressive effect on cytokine production (Figure 6A). This indicated that decreased concentrations of arginine impact CD8$^+$ T cell responses and that these effects are aggravated by a simultaneous increase of ornithine.

To experimentally uncouple the observed changes in the urea cycle from other co-occurring effects in vivo, we treated wild-type mice with recombinant pegylated human arginase 1 (recArg1) (Cheng et al., 2007) to aggravate the observed endogenous regulation of arginine and ornithine in the circulation. As expected, recArg1 converted arginine to ornithine in the serum and closely recapitulated the decreased arginine-to-ornithine ratio seen upon viral infection (Figures 5E and S6A). Administration of recArg1 did not affect the abundance of splenic T cells of infected and uninfected animals on day 8 after infection (Figure S6B). Yet, we recognized an impaired shift from naive (CD62L$^-$/CD44$^+$) to effector (CD62L$^-$/CD44$^+$) T cells (Figures S6C and S6D). Further, the numbers of virus-specific CD8$^+$ T cell responses were significantly lower in recArg1-treated mice than in non-treated mice (Figures S6E and S6F). These results are consistent with the impaired antigen-specific immune responses that were observed in our in vivo infection model.

**Figure 4. IFNAR1 Contributes to Infection-Induced Metabolic Reprogramming of Hepatocytes**

(A) Depiction of the urea cycle, expression, and concentrations of the associated genes and serum metabolites in naive and LCMV-clone-13-infected Alb-Cre ERT2 thra$^{fl/fl}$ (thra$^{1/2}$) and thra$^{1/2}$; Ifit1$^{−/−}$ mice (n = 3).

(B) Uniform Manifold Approximation and Projection (UMAP) clustering of single-cell RNA-seq data of primary hepatocytes sorted from naive or infected wild-type animals 2 days after LCMV infection.

(C and D) Expression levels and correlation with Ifit1 levels (IFN-I-stimulated gene) of (C) Otc and (D) Ass1 in hepatocytes isolated from naive versus infected animals (n = 2; pooled for each condition). Each dot represents a single hepatocyte.

(E) Representative immunohistochemical staining of OTC, ASS1, and STAT1 in liver sections of naive or LCMV-infected (2 and 8 days after infection) wild-type mice.

(F) Quantification of immunohistochemical staining of OTC, ASS1, and STAT1 using HistoQuest software (n = 4 and 8 pictures per mouse were quantified).

(G) Expression of Otc and Ass1 in sorted primary hepatocytes isolated from naive and LCMV-infected (2 and 8 days after infection) mice (n = 3).

For metabolite data in (A), one of two representative experiments is shown. For (B)–(G), single-cell transcriptomic and histological data are derived from one experiment. Symbols represent the arithmetic mean ± SEM; "p < 0.05; ""p < 0.01; """"p < 0.001 (Student’s t test). Log 2 fold changes and adjusted p values for single-cell RNA-seq data were computed as described in the STAR Methods. See also Figure S4.
T cells (Figure 6B) and their ability to produce the cytokines IFN-γ and TNF-α upon peptide re-stimulation (Figures 6C–6E) were diminished upon recArg1 treatment. Virus-specific CD4 T cells were similarly affected (Figure S6E). CD8 T cell effector function remained impaired in recArg1-treated animals at least up to 50 days after infection (Figure 6F) and coincided with elevated viral loads in blood (Figure 6G) and organs 8 and 50 days after infection (Figures S6F–S6I). To investigate whether impaired cytokine production of CD8 T cells upon recArg1 treatment coincides with exhaustion, we analyzed PD1 expression on virus-specific CD8 T cells in the blood of mice 30 days after infection. This did not reveal any obvious differences for PD1 upon treatment with recArg1 (Figure S6J). Strikingly, treatment with recArg1 significantly ameliorated virus-induced CD8 T-cell-mediated tissue damage as determined by reduced serum concentration of ALT and AST (Figures 6H and 6I). We conclude that modulation of the systemic arginine-to-ornithine ratio regulates antiviral T cell responses to ameliorate virus-induced tissue damage.

**DISCUSSION**

Metabolic adjustments are crucial for activation and differentiation of immune cells (Jha et al., 2015; Pearce and Pearce, 2013; Pearce et al., 2009). Our study identified an IFNAR1-dependent mechanism whereby hepatocytes receive instructions to repress the transcription of genes with metabolic function. The role of IFN-repressed genes in disease and homeostasis is still poorly understood. Yet it is noticeable that IFN-I-driven expression signatures from other organs and cell types do not appear to feature similar global repressive gene regulation (Mostafavi et al., 2016; Schoggins et al., 2011). This potentially highlights a unique feature of the liver, which rapidly integrates inflammatory cues from the environment to modulate its intrinsic metabolism and, as a consequence, its systemic metabolic output to peripheral organs. This IFNAR1-mediated metabolic reprogramming of the liver may give rise to an unfavorable environment for pathogens (Sanchez et al., 2018), optimize the metabolic milieu for mounting adaptive immune responses (Ma et al., 2017), or...
instruct tissue repair and regeneration to prevent extensive tissue pathology. None of these options are mutually exclusive, and host damage control may be achieved by modulating disease tolerance and/or reducing immune effectors (Medzhitov, 2008).

Next to other metabolic changes, we identified a regulatory effect of IFNAR1 signaling on the urea cycle, a central metabolic pathway that is primarily expressed in the liver. Its primary function is the conversion of circulating toxic ammonia into non-toxic urea with a fumarate shunt connecting the urea cycle to the TCA cycle (Meijer et al., 1990). Fumarate can subsequently be metabolized to aspartate and \( \alpha \)-ketoglutarate, two major precursors of de novo amino acid synthesis. Hence, the urea cycle is a central metabolic pathway that is crucial for both detoxication as well as cellular proliferation (Watford, 2003).

We modeled the altered levels of serum arginine and ornithine upon viral infection by administration of recombinant arginase and demonstrate a suppressive effect on virus-specific CD8 T cell responses. This is in line with nutrient availability as an important factor that may either boost or dampen effector functions of T cells (Chang et al., 2015; Geiger et al., 2016; Johnson et al., 2018; Ma et al., 2017; Sinclair et al., 2013; Van de Velde and Murray, 2016). A recent study identified that T cells may actively shape serum metabolite levels themselves, thereby creating potential functional feedback loops between systemic metabolism and T cell activation (Miyajima et al., 2017). This study adds another regulatory layer next to well-established mechanisms, including T cell exhaustion, of how the host may fine-tune adaptive immunity during chronic infection (Wherry and Kurachi, 2015).

The urea cycle is linked to amino acid, polyamine, and nucleotide metabolic pathways and represents a major hub of systemic nitrogen metabolism, which contributes to the formation of advanced liver disease (Li et al., 2019). Accordingly, inherited urea cycle disorders (UCDs) and the resulting hyperammonemia with altered serum levels of the associated metabolites display severe health threats (Mew et al., 2003). We found that mice infected with LCMV display hyperammonemia, a hallmark of hepatic encephalopathy (Tranah et al., 2013). Additional investigations will be required to address whether infection-associated hyperammonemia may modulate sickness behavior and influence disease progression (Dantzer et al., 2008; Wang et al., 2019).

Downregulation or even loss of Otc and Ass1 are common features of many cancers, limiting aspartate consumption by the urea cycle and instead feeding into de novo nucleotide synthesis associated with tumor growth (Feun et al., 2012; Lam et al., 2011; Lee et al., 2018; Rabinovich et al., 2015). Otc and Ass1 are also crucial for de novo arginine synthesis. As a result, many tumors are auxotrophic for arginine, which renders

**Figure 6. Arginase 1 Treatment Reduces Antiviral CD8 T Cell Responses and Ameliorates Virus-Induced Hepatitis during LCMV CI13 Infection**

(A) IFN-\( \gamma \) and TNF-\( \alpha \) production of primary murine splenic CD8 T cells cultured in medium containing 1,150 \( \mu \)M (standard RPMI 1640 concentration) or 11.5 \( \mu \)M L-arginine with or without 1,150 \( \mu \)M L-ornithine upon CD3/28 activation for 3 days (\( n = 4 \)).

(B) GP33- and NP396-specific splenic tetramer* CD8 T cells (\( n = 5 \)).

(C–E) (C) GP33, (D) NP396, (E) GP276 virus-specific IFN-\( \gamma \) and TNF-\( \alpha \) producing virus-specific splenic CD8 T cells upon recArg1 treatment 8 days after LCMV clone 13 infection (\( n = 5 \)).

(F) IFN-\( \gamma \) and TNF-\( \alpha \) producing splenic GP33-specific CD8 T cells in mice treated with recArg1 twice per week up to 50 days after infection (\( n = 5 \)).

(G) Viral load in blood upon recArg1 treatment (\( n = 5 \)).

(H and I) Serum ALT (H) and AST (I) levels upon recArg1 treatment (\( n = 5 \)).

Data in (A)–(I) are representative for one of at least two experiments. Symbols represent the arithmetic mean ± SEM. Dotted line implicates limit of detection. *\( p < 0.05 \); **\( p < 0.01 \) (Student’s t test, A–F, H, and I, or two-way ANOVA, G). See also Figure S6.
arginine a metabolic vulnerability that is currently therapeutically exploited by recArg1 treatment of cancer patients (De Santo et al., 2018). In line, UCDs and in particular Ass1 deficiency of tumors potentially synergize with checkpoint blockade treatment in tumors (Lee et al., 2018). Interestingly, reduced serum levels of arginine are associated with less liver tissue damage in chronic HBV infection although increased serum levels of arginine and arginine derivatives have been associated with non-alcoholic fatty liver disease (Dumas et al., 2014; Li et al., 2011; Pallett et al., 2015; Soga et al., 2011). Finally, deregulated ornithine metabolism and increased synthesis of polyamines may also impact cellular proliferation as well as the replication of diverse groups of viruses, potentially impacting on infection-associated cancer formation and progression (Casero et al., 2018; Mounce et al., 2016).

Using different approaches, we demonstrate that virus-induced IFNAR1 signaling in hepatocytes leads to downregulation of Otc and Ass1. The simultaneous upregulation of Arg1 during viral infection of the liver suggests that, during infection, hepatocytes are reprogrammed toward increased arginine degradation and ornithine accumulation. However, we cannot exclude the possibility that infiltrating immune cells, including myeloid-derived suppressor cells (MDSCs), may contribute to increased Arg1 expression in the liver (Gabrilovich, 2017). In line with this, our 13C2-labeled experiments confirmed that viral infection increases the hepatic conversion of arginine to ornithine and correlates with systemic accumulation of ornithine and citrulline. The observed infection-dependent decrease of the urea cycle end product 13C0 arginine further supported the notion of an IFNAR1-mediated break of the urea cycle. Still, these results do not rule out the potential additional contributions of extrahepatic events, as changes in the endocrine system are likely co-occurring with systemic metabolic reprogramming and/or sickness behavior during infection. Previous studies also established a link between hepatic autophagy, hepatocyte-derived circulating ARG1, and the systemic arginine-to-ornithine ratio, leading to reduced tumor growth in mice (Poliit-Perez et al., 2018). These lines of evidence suggest that endogenous metabolic reprogramming of the urea cycle modulates the pathophysiology during infectious disease. Our results may also provide a potential explanation for why many non-hepatotropic infections result in concomitant hepatitis (Adams and Hubscher, 2006; Lalazar and Ilan, 2014).

Taken together, our study provides evidence for an infection-induced reprogramming of the urea cycle in hepatocytes, a central metabolic pathway in the liver, leading to hyperammonemia and liver disease. We identified hepatocyte-intrinsic IFNAR1 signaling as a key regulator of circulating levels of arginine and ornithine to fine-tune adaptive immunity. This endogenous cytokine-driven mechanism of immunomodulation and host protection across organs could be targeted to ameliorate tissue pathology in infectious and inflammatory diseases.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **LEAD CONTACT AND MATERIALS AVAILABILITY**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Mice
  - Viruses and cell lines
- **METHOD DETAILS**
  - Infections
  - Pharmacological perturbations
  - Conditional Ifnar1 ablation on hepatocytes
  - poly(I:C) treatment
  - Isolation of primary murine hepatocytes
  - Metabolite tracing
  - Enzymatic assays
  - Gene expression analyses of sorted primary murine hepatocytes
  - Immunohistochemistry
  - Cytokine determination
  - Blood chemistry
  - RNA isolation and real-time PCR
  - Metabolic flux measurements
  - CD8 T cell isolation and in vitro activation
  - Flow cytometry
  - Quantitative proteomics
  - Targeted LC-MS based metabolite measurements
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - RNA-seq data processing
  - Single cell RNA-seq processing
  - Principal component analysis
  - Hierarchical clustering
  - Interaction model
  - Enrichments and pathway analyses
  - Mass spectrometry data processing
  - Targeted LC-MS based metabolite quantification
  - Metabolite tracing quantification
  - Immunohistochemistry quantification
  - Statistical information
- **DATA AND CODE AVAILABILITY**

**SUPPLEMENTAL INFORMATION**

Supplemental Information can be found online at https://doi.org/10.1016/j.immuni.2019.10.014.

A video abstract is available at https://doi.org/10.1016/j.immuni.2019.10.014#mmc6.

**ACKNOWLEDGMENTS**

We want to thank Sarah Niggemeyer, Jenny Riede, Sabine Jungwirth, Nicole Fleischmann, and Patricia Schittenhelm for animal caretaking; Safia Zahma for histopathology and immunohistochemistry processing; Thomas Penz, Michael Schuster, Martin Senekowitsch, Daniele Barreca, and Christoph Bock from the Biomedical Sequencing Facility at CeMM; Katja Parapaties from the Proteomics Facility at CeMM; Jacques Colinge for initial data analyses; and Christoph J. Binder from CeMM and Medical University of Vienna and Roger Geiger from the Institute for Research in Biomedicine, Bellinzona, for support and feedback. The following reagents were obtained through the NIH Tetramer Core Facility: LCMV MHCI tetramers GP33 (in Phycoerythrin [PE]) and NP396 (in Allophycocyanin [APC]). This project was funded with support of the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 677006, “CMIL” to A. Berghaierl). A.L., A. Bhattacharyya, and J.S.B. were supported by a DOC fellowship of the Austrian Academy of Sciences. N.P. was supported
formed

AUTHOR CONTRIBUTIONS

A.L., A.M.P., and A. Berghalter wrote the manuscript. A.L. designed and performed in vivo and in vitro studies. A. Bhattacharya, M.F.S., B.A., L.K., T.P., J.-W.G., and N.P. performed in vitro and/or in vivo experiments. D.V., P.M., and K.L.B. contributed to proteomic analyses. A.L., A.M.P., M.C., and J.M. performed bioinformatic analyses. K.K., B.G., D.R., and M.O.-K. performed metabolite measurements. A.O. performed histological analyses. U.K. and P.N.C. provided reagents. H.B., G.S., J.S.B., B.L., R.M., and M.T. analyzed data and provided feedback. A. Berghalter supervised the study and designed and analyzed experiments.

DECLARATION OF INTERESTS

P.N.C. is the founder of Biocancer Treatment International, and G.S. is scientific advisor of Biocancer Treatment International.

Received: May 22, 2019
Revised: September 10, 2019
Accepted: October 25, 2019
Published: November 26, 2019

REFERENCES

Adams, D.H., and Hubscher, S.G. (2006). Systemic viral infections and collateral damage in the liver. Am. J. Pathol. 168, 1057–1059.
Mew, N.A., Simpson, K.L., Gropman, A.L., Lanpher, B.C., Chapman, K.A., and Summar, M.L. (2003). Urea cycle disorders overview. In GeneReviews, M.P.
Thiel, V., and Ludewig, B. (2007). Control of coronavirus infection through plasminogen.
J Proteomics 74, 151–156.
Bhattacharya, A., Hegazy, A.N., Deigendesch, N., Kosack, L., Cupovic, J., Kundasamy, R.K., Hildebrandt, A., Kühler, A.A., Vilagos, B., et al.
(2015). Superoxide dismutase 1 protects hepatocytes from type I interferon-driven oxidative damage. Immunity 43, 974–986.
Bindea, G., Miclén, B., Hacki, H., Charoentong, P., Tosolini, M., Krivolysov, A., Fridman, W.-H., Pagès, F., Trajanoski, Z., and Galon, J. (2009). ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091–1093.
Breitwieser, F.P., and Colinge, J. (2013). IsoBar[PTM]: a software tool for the quantitative analysis of post-translationally modified proteins. J Proteomics 90, 77–84.
Breitwieser, F.P., Müller, A., Dayon, L., Köcher, T., Hainard, A., Pichler, P., Schmidt-Erfurth, U., Superti-Furga, G., Sanchez, J.-C., Mechtler, K., et al. (2011). General statistical modeling of data from protein relative expression isotopic tags. J Proteome Res. 10, 2758–2766.
Buck, M.D., Sowell, R.T., Kaech, S.M., and Pearce, E.L. (2017). Metabolic instruction of immunity. Cell 179, 570–586.
Casero, R.A., Jr., Murray Stewart, T., and Pegg, A.E. (2018). Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat. Rev. Cancer 18, 681–695.
Cervantes-Barragan, L., Lust, R., Weber, F., Spiegel, M., Lang, K.S., Akira, S., Thiet, V., and Ludewig, B. (2007). Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood 109, 1131–1137.
Chang, C.H., Qiu, J., O’Sullivan, D., Buck, M.D., Noguchi, T., Curtis, J.D., Chen, Q., Gindin, M., Gubin, M.M., van der Windt, G.J.W., et al. (2015). Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229–1241.
Cheng, P.N.-M., Lam, T.-L., Lam, W.-M., Tsui, S.-M., Cheng, A.W.-M., Lo, W.-H., and Leung, Y.-C. (2007). Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits in the vitro and in vivo proliferation of human hepatocellular carcinoma through arginase depletion. Cancer Res. 67, 309–317.
Crispe, I.N. (2016). Hepatocytes as immunological agents. J. Immunol. 196, 17–21.
Dantzker, R., O’Connor, J.C., Freund, G.G., Johnson, R.W., and Kelley, K.W. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46–56.
De Santo, C., Cheng, P., Beggs, A., Egan, S., Bessudo, A., and Mussai, F. (2018). Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma. J. Hematol. Oncol. 11, 68.
Dyez-Fernandez, C., Wellauer, O., Gemperle, C., Rüfenacht, V., Fingerth, R., and Häberle, J. (2016). Kinetic mutations in argininosuccinate synthetase deficiency: characterisation and in vitro correction by substrate supplementation. J. Med. Genet. 53, 710–719.
Dumas, M.-E., Kinross, J., and Nicholson, J.K. (2014). Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology 146, 46–62.
Feun, L.G., Marini, A., Walker, G., Elgart, G., Moffat, F., Rodgers, S.E., Wu, C.J., You, M., Wangpaichitr, M., Kuo, M.T., et al. (2012). Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine dermase. Br. J. Cancer 106, 1481–1485.
Gabrilovich, D.I. (2017). Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3–8.
Geiger, R., Rieckmann, J.C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. (2016). L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167, 829–842.e13.
Guerrero, J.R., Lameu, C., Oliveira, E.F., Kiltzke, C.F., Melo, R.L., Linares, E., Augusto, O., Fox, J.W., Lebrun, I., Serrano, S.M.T., and Camargo, A.C. (2009). Argininosuccinate synthetase is a functional target for a snake venom anti-hypertensive peptide: role in arginine and nitric oxide production. J. Biol. Chem. 284, 20022–20033.
Guidotti, L.G., Borrow, P., Brown, A., McClary, H., Koch, R., and Chisari, F.V. (1999). Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte. J. Exp. Med. 179, 1555–1564.
Hafemeister, C., and Satija, R. (2019). Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. bioRxiv. https://doi.org/10.1101/576827.
Halpern, K.B., Shenhav, R., Matcovitch-Natan, O., Töth, B., Lemez, D., Golan, M., Massasa, E.E., Baydatch, S., Landen, S., Moor, A.E., et al. (2017). Single-cell spatial reconstruction reveals global division of labour in the mammalian liver. Nature 542, 352–356.
Hotamisligil, G.S. (2017). Inflammation, metaflammation and immunometabolic disorders. Nature 542, 177–185.
Jenne, C.N., and Kubes, P. (2013). Immune surveillance by the liver. Nat. Immunol. 14, 996–1006.
Jha, A.K., Huang, S.C.C., Sergushichev, A., Lampropoulou, V., Ivanova, Y., Loginchina, E., Chmielewski, K., Stewart, K.M., Ashall, J., Everts, B., et al. (2015). Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 42, 419–430.
Johnson, M.O., Wolf, M.M., Madden, M.Z., Andrejeva, G., Sugiura, A., Contreras, D.C., Maseda, D., Lobero, M.V., Paz, K., Kishton, R.J., et al. (2018). Distinct regulation of Th17 and Th1 cell differentiation by glutamine-dependent metabolism. Cell 175, 1780–1795.e19.
Kamphuis, E., Junt, T., Walier, Z., Forster, R., and Kalinke, U. (2006). Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108, 3253–3261.
St John-Williams, L., Blach, C., Toledo, J.B., Rotroff, D.M., Kim, S., Klavins, K., Baillie, R., Han, X., Mahmoudiandehkordi, S., Jack, J., et al.; Alzheimer’s Disease Neuroimaging Initiative; Alzheimer’s Disease Metabolomics Consortium (2017). Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Sci. Data 4, 170140.

Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., Hao, Y., Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive integration of single-cell data. Cell 177, 1888–1902.e21.

Sturman, L.S., and Takemoto, K.K. (1972). Enhanced growth of a murine coro-navirus in transformed mouse cells. Infect. Immun. 6, 501–507.

Tranah, T.H., Vijay, G.K.M., Ryan, J.M., and Shawcross, D.L. (2013). Systemic inflammation and ammonia in hepatic encephalopathy. Metab. Brain Dis. 28, 1–5.

Uhlen, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Â., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015). Tissue-based map of the human proteome. Science 347, 1260419.

Van de Velde, L.A., and Murray, P.J. (2016). Proliferating helper T cells require rictor/mTORC2 complex to integrate signals from limiting environmental amino acids. J. Biol. Chem. 291, 25815–25822.

van den Berghe, G. (1991). The role of the liver in metabolic homeostasis: implications for inborn errors of metabolism. J. Inherit. Metab. Dis. 14, 407–420.

Virgin, H.W., Wherry, E.J., and Ahmed, R. (2009). Redefining chronic viral infection. Cell 138, 30–50.

Wang, A., Luan, H.H., and Medzhitov, R. (2019). An evolutionary perspective on immunometabolism. Science 363, 80.

Watford, M. (2003). The urea cycle: teaching intermediary metabolism in a physiological setting. Biochem. Mol. Biol. Educ. 31, 289–297.

Wherry, E.J., and Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486–499.

Wisniewski, J.R., Zougman, A., Nagaraj, N., and Mann, M. (2009). Universal sample preparation method for proteome analysis. Nat Methods 6, 359–362.

Wu, G., Bazer, F.W., Davis, T.A., Kim, S.W., Li, P., Marc Rhoads, J., Carey Satterfield, M., Smith, S.B., Spencer, T.E., and Yin, Y. (2009). Arginine metabolism and nutrition in growth, health and disease. Amino Acids 37, 153–168.

Wu, D., Sanin, D.E., Everts, B., Chen, Q., Qiu, J., Buck, M.D., Patterson, A., Smith, A.M., Chang, Ch.-H., Liu, Z., et al. (2016). Type 1 interferons induce changes in core metabolism that are critical for immune function. Immunity 44, 1325–1336.

York, A.G., Williams, K.J., Argus, J.P., Zhou, Q.D., Brar, G., Vergnes, L., Gray, E.E., Zhen, A., Wu, N.C., Yamada, D.H., et al. (2015). Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling. Cell 163, 1716–1729.

Zehn, D., and Wherry, E.J. (2015). Immune memory and exhaustion: clinically relevant lessons from the LCMV model. Adv. Exp. Med. Biol. 850, 137–152.

Zhou, Z., Xu, M.J., and Gao, B. (2016). Hepatocytes: a key cell type for innate immunity. Cell. Mol. Immunol. 13, 301–315.

Zinkernagel, R.M., Haenseler, E., Leist, T., Cerny, A., Hengartner, H., and Althage, A. (1986). T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay? J. Exp. Med. 164, 1075–1092.
### STAR★METHODS

#### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| anti-CD3e           | BD Biosciences | Cat#553238 |
| anti-CD28           | BD Biosciences | Cat#553295 |
| anti-CD8.2b:Pacific Blue, clone S3-5.8 | Biolegend | Cat#140414 |
| anti-CD4:FITC, clone H129.19 | Biolegend | Cat#100408Cat#130308 |
| anti-CD4:PE, clone GK1.5 | Biolegend | Cat#100408 |
| anti-CD3e:APC, clone 145-2C11 | Biolegend | Cat#100312 |
| anti-CD44:BV605, clone IM7 | Biolegend | Cat#103047 |
| anti-CD62L:AF700, clone MEL-14 | Biolegend | Cat#104426 |
| anti-CD19:APC-Cy7, clone 6D5 | Biolegend | Cat#103047 |
| anti-IFNα: PE-Cy7, clone XMG1.2 | Biolegend | Cat#505826 |
| anti-IL-2: PE, clone JES6-5H4 | Biolegend | Cat#503808 |
| anti-TNFα: APC, clone MP6-XT22 | Biolegend | Cat#506308 |
| anti-STAT1           | Cell Signaling Technology | Cat#9172 |
| anti-ASS1            | Abcam  | Cat#ab170952 |
| anti-OTC            | Santa Cruz | Cat#sc-5157791 |
| anti-CD16/32, clone: 93 | Biolegend | Cat#101330 |
| anti-CD16/32, clone: 93 | Biolegend | Cat#101330 |
| rat anti-IFN-α       | PBL Interferon Source | Cat#22100-1 |
| rabbit anti-IFN-α    | PBL Interferon Source | Cat#32100-1 |
| anti-rabbit HRP antibody | Jackson ImmunoReserach | Cat#711-036-152 |
| **Bacterial and Virus Strains** |        |            |
| MHV strain A59      | Cervantes-Barragan et al., 2007 | NA |
| LCMV strain Cl13    | Bhattacharya et al., 2015 | NA |
| **Chemicals, Peptides, and Recombinant Proteins** |        |            |
| Polyinosine-olycytidylic acid (poly(I:C)) | Invivogen | Cat#tlrl-pic |
| Recombinant murine IFNβ | PBL Assay Science | Cat#12405-1 |
| Recombinant murin IL-2 | Thermo Fisher Scientific | Cat#34-8021-82 |
| Liberase TM         | Sigma  | Cat#5401127001 |
| Tamoxifen           | Sigma  | Cat#T6568 |
| Sunflower oil       | Sigma  | Cat#S5007 |
| α-Methyl-DL-aspartic acid | Sigma | Cat#M6001 |
| L-Citrulline        | Sigma  | Cat#C7629 |
| L-Arginine          | Sigma  | Cat#A5006 |
| L-Ornithine         | Sigma  | Cat#O2375 |
| β-mercaptoethanol   | Sigma  | Cat#M6250 |
| 15C6 arginine       | Cambridge Isotope Laboratories | Cat#CLM-2265-H-PK |
| 15C6 ornithine      | Cambridge Isotope Laboratories | Cat#CLM-4724-PK |
| 17C4 aspartic acid  | Cambridge Isotope Laboratories | Cat#CLM-1801-H-PK |
| Carbamoyl phosphate | Sigma  | Cat#C4135 |
| Phosphatase inhibitor cocktail | Thermo Fisher Scientific | Cat#78447 |
| Adenosine triphosphate | Thermo Fisher Scientific | Cat#R1441 |
| QIAzol lysis reagent | Qiagen  | Cat#79306 |
| Roti histofix       | Carl Roth | Cat#P087.4 |

(Continued on next page)
## REAGENT or RESOURCE SOURCE IDENTIFIER

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Target retrieval solution | Dako | Cat#S1699 |
| Taqman fast universal PCR mastermix | Thermo Fisher Scientific | Cat#4352042 |
| Agilent Seahorse XF base medium | Agilent | Cat#102353-100 |
| Red blood cell lysis buffer | eBioscience | Cat#00-430054 |
| RPMI 1640 medium for SILAC | Thermo Fisher Scientific | Cat#88365 |
| Dialyzed FCS | Thermo Fisher Scientific | Cat#A3382001 |
| Heparin-Natrium-5000-ratiopharm | Ratiopharm | NA |
| Xylapan | Vetoquinol | NA |
| Narketan | Vetoquinol | NA |
| GP33-PE | NIH tetramer core facility | NA |
| NP396-APC | NIH tetramer core facility | NA |
| Protein transport inhibitor cocktail | eBioscience | Cat#00-4980-03 |
| Cell stimulation cocktail | eBioscience | Cat#00-4970-93 |
| Saponin | Sigma | Cat#47036 |
| LCMV gp33-41 peptide (KAVYNFATC) | Peptide 2.0 Inc. | custom synthesis |
| LCMV np396-404 peptide (FQPQNGAFI) | Peptide 2.0 Inc. | custom synthesis |
| LCMV gp276-286 peptide (SGVENPGGYCL) | Peptide 2.0 Inc. | custom synthesis |
| LCMV gp64-80 peptide (GPDIYKGVYQFKSVEFD) | Peptide 2.0 Inc. | custom synthesis |
| Pegylated recombinant human ARG1 | Bio-Cancer Treatment International Ltd. | Cat#PEG-BCT-100 |
| Recombinant murine IFNα | PBL Interferon Source | Cat#12100-1 |
| TMB Solution | Thermo Fisher Scientific | Cat#002023 |

## Critical Commercial Assays

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Agilent Seahorse XF Cell Mito Stress Test Kit | Agilent | Cat#10315-100 |
| CD8α+ T Cell Isolation Kit | Miltenyi Biotec | Cat#130-104-075 |
| Absolute IDQ P180 Kit | Biocrates Life Sciences AG | NA |
| Precellys CK14 Lysing Kit | VWR | Cat#132-3751 |
| RevertAid First Strand cDNA Synthesis Kit | Thermo Fisher Scientific | Cat#K1612 |

## Deposited Data

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Proteomic data | This study | PRIDE: PXD011122 |
| Transcriptomic data (superfamily) | This study | GEO: GSE123688 |

## Experimental Models: Organisms/Strains

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Mouse:Cre-Alb ERT2 | Schuler et al., 2004 | NA |
| Mouse:ifnar1−/− | Muller et al., 1994 | NA |
| Mouse:ifnar1R/R | Kamphuis et al., 2006 | NA |

## Oligonucleotides

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| E11α Taqman primers and probes | Bhattacharya et al., 2015 | NA |
| Otc Taqman Gene Expression Assay | Thermo Fisher Scientific | Cat#Mm00493267_m1 |
| Ass1 Taqman Gene Expression Assay | Thermo Fisher Scientific | Cat#Mm00711256_m1 |
| LCMV NP Taqman primers and probes | Bhattacharya et al., 2015 | NA |

## Software and Algorithms

| SOFTWARE or ALGORITHM | SOURCE | IDENTIFIER |
|-----------------------|--------|------------|
| FlowJo v8.7 | FlowJo | FlowJo |
| Trace Finder v4.1 | Thermo Fisher Scientific | Trace Finder |
| Cell Ranger v3.0.2 | 10X Genomics | CellRanger |
| MetaIDQ, Version 5-4-8-DB100-Boron-2607 | Biocrates Life Sciences AG | MetaIDQ |
| HistoQuest TM software | TissueGnostics GmbH | HistoQuest |
| Xcalibur v2.1 | Thermo Fisher Scientific | Xcalibur |
| ExpressCluster v1.3 | Harvard Medical School | ExpressCluster |
| ClueGO v2.3.3 | Bindea et al., 2009 | Cytoscape ClueGO |

(Continued on next page)
LEAD CONTACT AND MATERIALS AVAILABILITY

Inquires for further information or requests for resources and reagents should be directed and will be fulfilled by the lead contact Andreas Bergthaler (abergthaler@cemm.oeaw.ac.at). This study did not generate new unique reagents.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

**Mice**

C57BL/6J mice were originally obtained from The Jackson Laboratory, *Ifnar1<sup>fl/fl</sup>* mice from Ulrich Kalinke (TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany) and *Cre-Alb ERT2* mice from Pierre Chambon (Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France). Mice were bred and maintained under specific pathogen-free (SPF) conditions at the Institute for Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria. Animal experiments were conducted in individual ventilated cages according to the respective animal experiment licenses (BMWFW-66.009/0199-WF/V/3v/2015 and BMWFW-66.009/0361-WF/V/3b/2017) approved by the institutional ethical committees and the institutional guidelines at the Department for Biomedical Research of the Medical University of Vienna. Mice were 8 to 12 weeks old and age- and sex-matched within experiments. Male and female mice were used interchangeably between experiments and no striking sex-differences were observed. For experiments using murine hepatitis virus (MHV), mice were maintained under SPF conditions at the Kantonsspital St. Gallen Medical Research Center, St. Gallen Switzerland. MHV experiments were conducted in individually ventilated cages according to the animal experiment license (SG/14/18.30861) approved by federal and cantonal ethical committees.

**Viruses and cell lines**

Lymphocytic choriomeningitis virus (LCMV) was grown on BHK-21 cells (baby hamster kidney cells derived from 5 unsexed newborns, ATCC CCL-10) and titer was determined in a modified focus forming assay using Vero cells (female green monkey kidney cells, ATCC CCL-81) (Bhattacharya et al., 2015). Mice were intravenously infected with 2x10<sup>6</sup> focus forming units (FFU) of LCMV.

Murine hepatitis virus strain A59 (MHV) was generated using 17CL1 cells (spontaneously transformed 3T3 cell line established from unsexed BALB/c mouse embryos) (Sturman and Takemoto, 1972) and titer was determined by standards plaque assay on L929 cells (male murine fibroblasts, ATCC CCL-1) (Cervantes-Barragan et al., 2007). Mice were intraperitoneally infected with 10<sup>3</sup> plaque forming units (PFU) of MHV.

METHOD DETAILS

**Infections**

Mice were sacrificed at the time points indicated in the legends. Tissue samples were snap frozen in liquid nitrogen and stored at −80°C until further analyses. For serum collection, blood was collected at the respective time points, samples were centrifuged at 10,000 rpm for 5 min at 4°C. The serum was transferred into a new tube and stored at −80°C until further analyses.

**Pharmacological perturbations**

Pegylated recombinant human Arginase 1 (PEG-BCT-100, Bio-Cancer Treatment International) was administered to mice via intraperitoneal injection at a dosage of 50 mg/kg. Mice were treated twice per week. Treatment was started one day prior to LCMV infection. Control mice received the same volume of PBS.
Conditional Ifnar1 ablation on hepatocytes
Tamoxifen (T5658, Sigma) was dissolved in sterile sunflower oil (S5007, Sigma) containing 10% ethanol (v/v) and stored at −20°C for a maximum of 2 weeks. To induce hepatic Ifnar1 ablation, Cre-Alb ERT2 Ifnar1+/− and Cre-Alb ERT2 Ifnar1−/− control mice were administered 50 mg/kg tamoxifen intraperitoneally for 5 consecutive days (Metzger et al., 2005). Experiments were started the day after the last dose.

poly(I:C) treatment
Mice were challenged with poly(I:C) (invivogen, #tlrl-pic) via intraperitoneal injection at a dosage of 4 mg/kg. Control mice received PBS. Liver tissue was harvested and analyzed via real-time PCR at the indicated time points.

Isolation of primary murine hepatocytes
Mice were anesthetized (ketamine/xylazine: 1:3, 0.1 ml/10 g mouse, Vetoquinol) and the liver was cannulated via the portal vein and perfused with 20 mL HBSS (GIBCO) containing 0.5 mM EGTA (Sigma) followed by digestion of the liver with 20 mL L15 medium (GIBCO) containing 40 mg/L Liberase (Roche) at a rate of 5 mL/min. The liver was isolated, placed in a Petri dish with digestion medium (L15 with 40 mg/L Liberase) and the liver capsule was diligently removed. Cells were centrifuged at 50 g for 5 min at 4°C, re-suspended in William’s E medium containing 10% FCS (PAA) and 1% Penicillin-Streptomycin-Glutamine (Thermo Fisher Scientific) and plated. Cells were stimulated at the time of plating.

Metabolite tracing
Naive or LCMV-infected C57BL/6J mice were given an intravenous bolus of 500 μg 13C6 labeled arginine (Cambridge Isotope Laboratories, CLM-2265-H-PK) dissolved in PBS. Mice were sacrificed 20 min afterward and serum and tissues of interest were harvested and stored at −80°C.

Per mg tissue (approximately 100 mg per sample), 3 μL 80% (v/v) methanol were added and tissue samples were homogenized using a Precelllys 24 tissue homogenizer (Precelllys CK14 lysing kit, Bertin). 50 μL of homogenized tissue or serum were mixed with 450 μL of methanol and 250 μL of water and vortexed for 10 s. Afterward, 450 μL chloroform were added per sample and mixed by vortexing for 10 s, incubated on ice for 5 min and vortexed again for 10 s before centrifuging them for 10 min at 1000 g. The upper aqueous phase was collected, dried (nitrogen evaporator) and reconstituted in 50 μL of methanol. Samples were centrifuged for 10 min at 1000 g and supernatants were used for LC-MS analysis.

A Vanquish UHPLC system (Thermo Scientific) coupled to an Orbitrap Fusion Lumos (Thermo Scientific) mass spectrometer was used for the LC-MS analysis. The chromatographic separation for samples was carried out on an ACQUITY UPLC BEH Amide, 1.7 μm, 2.1×100 mm analytical column (Waters) equipped with a VanGuard: BEH C18, 2.1x5mm pre-column (Waters). The column was maintained at a temperature of 40°C and 2 μL sample were injected per run. The mobile phase A was 0.15% v/v formic acid in water and mobile phase B was 0.15% v/v formic acid in 85% v/v acetonitrile with 10 mM ammonium formate. The gradient elution with a flow rate 0.4 mL/min was performed with a total analysis time of 17 min. The mass spectrometer was operated in a positive electrospray ionization mode: spray voltage 3.5 kV; sheath gas flow rate 60 arb; auxiliary gas flow rate 20 arb; capillary temperature 285°C. For analysis, a full MS scan mode with a scan range m/z 50 to 400, resolution 120.000, AGC target 2e5 and a maximum injection time 50 ms was applied. For detection of urea the scan range was adjusted to m/z 50 to 250 at a resolution of 500.000.

Enzymatic assays
Liver tissue lysis and buffer conditions for enzymatic assays for OTC and ASS1 were previously described (Diez-Fernandez et al., 2016; Guerreiro et al., 2009). Briefly, liver tissue was lysed in 10 mM HEPES, 0.05% Triton X-100, 0.5 mM DTT, 1 mM L-Aspartate-13C4 (Cambridge Isotope Laboratories, CLM-1801-H-PK), 1 mM Carbamoyl Phosphate (Sigma, C4135), 1X Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, 78447), pH 7.4 and samples were incubated for 30 min at 37°C. For ASS1 activity, 200 μM of 20 mM HEPES, 2 mM ATP (Thermo Fisher Scientific, R1441), 5 mM MgCl2, 1 mM L-Aspartate-13C4 (Cambridge Isotope Laboratories, CLM-1801-H-PK), 1 mM L-Citrulline (Sigma, C7629), 1X Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, 78447), pH 7 and samples were incubated for 30 min at 37°C. For experiments using the ASS1-specific inhibitor α-Methyl-DL-aspartic acid (MDLA, M6001, Sigma), 100 μg of total liver protein extract were treated with 10 mM MDLA and the enzymatic assay was performed as described above (Guerreiro et al., 2009).

Following the incubation, 10 μL of sample was immediately mixed with 90 μL methanol and subsequently prepared for mass spectrometric analysis of labeled downstream metabolites. 13C labeled argininosuccinate or 13C labeled citrulline was detected using a Vanquish UHPLC system (Thermo Scientific) coupled to an Orbitrap Fusion Lumos (Thermo Scientific) mass spectrometer was used for the LC-MS analysis. The chromatographic separation for samples was carried out on an ACQUITY HSS T3, 1.8 μm, 2.1x100 mm analytical column (Waters) equipped with a VanGuard HSS T3, 2.1x5 mm pre-column (Waters). The column was maintained at a temperature of 40°C and 2 μL sample were injected per run. The mobile phase A was 0.1% formic acid (v/v) in water and mobile phase B was 0.1% formic acid (v/v) in methanol. The gradient elution with a flow rate 0.5 mL/min was performed with a total analysis time of 10 min. The mass spectrometer was
operated in a positive electrospray ionization mode; spray voltage 3.5 kV; sheath gas flow rate 60 arb; auxiliary gas flow rate 20 arb; capillary temperature 285°C. For the analysis a full MS scan mode with a scan range m/z 80 to 400, resolution 500,000, AGC target 2e5 and a maximum injection time 50 ms was applied.

**Gene expression analyses of sorted primary murine hepatocytes**

Primary murine hepatocytes from naive or LCMV Cl13 infected female animals were isolated as described above. After isolation, cells derived from one liver were resuspended in 500 μL PBS containing anti-CD16/32 (1:200, clone: 93, Biolegend) and incubated for 10 min at room temperature. Next, immune cells (CD45.2: PE clone: 104, Biolegend, 1:200) and dead cells (Fixable Viability Dye: eFluor 780, eBioscience, 1:2000) were stained for 20 min at 4°C. Cells were washed with PBS and 50,000 to 200,000 hepatocytes (viable CD45.2⁺, purity > 95%) were sorted into PBS containing 0.04% BSA on a Sony SH800 Cell Sorter using a 130 μm chip and used for gene expression analyses. For real-time PCR analyses, cells from each mouse (n = 3) were centrifuged at 1500 rpm for 5 min and resuspended in QIAzol for further analyses. For single cell RNA-seq, cells from 2-3 mice were pooled in equal amounts, centrifuged, and resuspended in PBS containing 0.04% BSA to obtain a concentration of 800,000 cells/mL. This cells suspension was subsequently used for droplet based single cell RNA-seq using a 10X Genomics Chromium Single Cell Controller and standard protocols. Samples were sequenced with an Illumina HiSeq 3000/4000 instrument with 3 samples multiplexed per lane and run on a 75bp paired-end flow cell.

**Immunohistochemistry**

Liver pieces were fixed in Roti Histofix (P087.4, Carl Roth) for 48h. Afterward the fixation solution was exchanged to 70% (v/v) ethanol and stored until paraffin-embedment. For immunohistochemical stainings 2 μm FFPE consecutive sections cut, heat-mediated antigen retrieval was performed in citrate buffer at pH 6.0 (S1699; Dako, Agilent, Santa Clara, CA, USA). Sections were stained with antibodies specific to STAT1 monoclonal rabbit (1:200; sc-5157791; Santa Cruz), ASS1 monoclonal rabbit (1:400; ab170952; Abcam), OTC monoclonal rabbit (1:500, sc-5157791; Santa Cruz), using standard protocols.

**Cytokine determination**

IFN-α serum levels were determined via enzyme-linked immunosorbent assay (ELISA) as described previously (Bhattacharya et al., 2015). In brief, microplates (675074, Greiner Bio-One) were coated with rat anti-mIFN-α capture antibody (22100-1, PBL Interferon Source, 1:54 dilution in PBS). Pre-diluted serum samples (1:10 to 1:20 in PBS) and mIFN-α standards (12100-1, PBL Interferon Source) were added and incubated in a humidified chamber overnight at 4°C. For detection, a primary rabbit anti-mIFN-α antibody (32100-1, PBL Interferon Source, 1:738 dilution in PBS), a secondary anti-rabbit HRP antibody (711-036-152, Jackson ImmunoResearch) and TMB solution (002023, Thermo Fisher Scientific) were used. The color reaction was read out on a plate reader at 450 nm.

**Blood chemistry**

Mouse serum was pre-diluted 1:8 in PBS and levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were spectrophotometrically analyzed using a Cobas C311 Analyzer (Roche). For blood ammonia, mice were terminally anesthetized (Ketamine/Xylazine: 1:3, 0.1 ml/10 g mouse, Vetoquinol) and blood was sampled via heart puncture. Blood was collected in MiniCollect blood EDTA tubes (Greiner Bio-One). Plasma was obtained by centrifugation of whole blood at 4,000 rpm for 10 min at 4°C and pre-diluted 1:1 in 0.9% (w/v) NaCl solution. Samples were kept on ice, in the dark and in closed tubes until analysis of blood ammonia on a Cobas 8000 analyzer (Roche).

**RNA isolation and real-time PCR**

Tissues were homogenized using a tissueLyser II (Qiagen). Total RNA was extracted from homogenized liver tissue using QIAzol lysis reagent as per the manufacturer’s instructions (79306, Qiagen). Reverse transcription from RNA to cDNA was carried out using random primers and the First Strand cDNA Synthesis Kit (K1612, Thermo Fisher Scientific). Real-time PCR was performed with Taqman Fast Universal PCR Mastermix (432042, Thermo Fisher Scientific) and Taqman Gene Expression Assays (Thermo Fisher Scientific) for Otc (Mm00493267_m1) and Ass1 (Mm00711256_m1). Expression levels of LCMV NP (5'-CAAGTATTCACACGGCATGGA-3' and 5'-GGCCTTGGTTCAGGATA-3') and 511a (5'-GCAAAACGACCACACAATG-3', 5'-GGGCTCTGTTACAGGATA-3' and 5'-GAGMCACTGAGCTGAAAGCCAG[TAM]-3') were measured by corresponding probe and primer sets as described previously (Bhattacharya et al., 2015).

**Metabolic flux measurements**

Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were determined on a Seahorse XF Analyzer (Agilent) using the Seahorse XF Cell Mito Stress test kit (Agilent, 103015-100). 25.000 primary hepatocytes were plated per well respectively. In brief, cells were treated with selected stimuli for the indicated time points. Prior to measurement, media was changed to XF Base Medium (Agilent 102353-100) containing glucose (10 mM), sodium pyruvate (1 mM) and L-glutamine (2 mM) and cells were incubated

---

**Reference**

Bhattacharya, A. et al. (2015). *Immunity* 51, 1074–1087.e1–e9, December 17, 2019.
for 1h. The assay was run according to the manufacturer’s instructions. Oligomycin (2 µM), Carbonyl cyanide-p-trifluoromethoxyphenoxyhydrozone (FCCP, 0.25 µM) and Rotenone/Antimycin A (500 nM) were subsequently injected into wells at the desired time points. Raw data were analyzed using Wave Desktop Software (Agilent, version 2.0) and exported and graphed in GraphPad Prism (GraphPad Software, version 7.0a).

**CD8 T cell isolation and in vitro activation**

Spleens of mice were harvested and dissociated through a 40 µm cell strainer (Falcon). The pellet was resuspended in 1 mL red blood cell lysis buffer (eBioscience, #00-4300-54) and incubated at room temperature for 1 min. Subsequently the reaction was stopped by addition of 9 mL PBS. Cells were counted and CD8 T cells isolated using a magnetic activated cell sorting negative selection (MACS) kit according to the manufacturer’s instructions (Miltenyi Biotec, #130-104-075). 96 well plates were coated over night at 4°C with 1 µg/mL anti CD3e (BD, #553238) and 2 µg/mL anti CD28 (BD, #553295) in a total volume of 60 µL PBS per well. Wells were washed with PBS and 5x10⁴ cells were plated per well in RPMI 1640 medium for SILAC (Thermo Fisher Scientific, #88365), supplemented with 10% dialyzed FCS (Thermo Fisher Scientific, #A3382001), 1% Penicillin-Streptomycin-Glutamine (Thermo Fisher Scientific), 50 µM β-mercaptoethanol (Sigma, #M6250) and 20 U/mL IL-2 (Thermo Fisher Scientific, #34-8021-82). Medium was supplemented with indicated concentrations of L-arginine (Sigma, #A5006) and/or L-ornithine (Sigma, #O2375) and cultured up to 72h before proceeding with intracellular cytokine staining.

**Flow cytometry**

To sample blood, 3–4 drops of blood were collected in 1 mL MEM medium (GIBCO) supplemented with 2000 U/L heparin (Heparin-Natrium-5000-ratiopharm). Red blood cells were lysed by adding 500 µL red blood cell lysis buffer (eBioscience, #00-4300-54) and incubated at room temperature for 1 min. Samples were spun down (1500 rpm), resuspended in 100 µL PBS and plated in a 96 well plate. Spleens were dissociated into a single cell suspension using a 40 µm cell strainer (Falcon) and resuspended in 10 mL of PBS (GIBCO). An aliquot of cell suspension was used for counting to calculate total number of cells per spleen. 200 µL per sample (approx. 2x10⁶ cells) were plated in a 96 well plate. Plates were spun and supernatants were removed.

For tetramer staining, cells were resuspended in 25 µL PBS containing GP33 (1:500) and NP396 (1:250) tetramers (NIH Tetramer Core Facility) and incubated at 37°C for 15 min. Next, 25 µL PBS containing anti-CD16/32 (Biolegend; 1:200, clone: 93) were added and incubated for 10 min at room temperature. 25 µL of a master mix of the desired surface marker antibodies (CD8.2b: Pacific Blue clone 53-5.8; CD4: FITC, clone H129.19; CD4: PE, clone GK1.5; CD3: APC, clone 145-2C11; CD44: BV605, clone IM7; CD62L: AF700, clone MEL-14; CD19: APC-Cy7, clone 6D5; all Biolegend; 1:200 in PBS) and Fixable Viability Dye eFluor 780 (eBioscience; 1:2000 in PBS) were added and cells were incubated for 20 min at 4°C. Cells were washed with FACS buffer (PBS, 2% FCS) and fixed in 4% Paraformaldehyde (Sigma) in PBS for 10 min. Subsequently samples were washed twice with FACS buffer, resuspended in 100 µL and analyzed by flow cytometry.

For intracellular cytokine staining (ICS), cell pellets were resuspended in 50 µL of RPMI 1640 medium (GIBCO) supplemented with 10% FCS (PA) and 1% Penicillin-Streptomycin-Glutamine (Thermo Fisher Scientific), 50 µM β-mercaptoethanol (Sigma), containing LCMV peptides (1:1000, Peptide 2.0 Inc.) and Protein Transport Inhibitor Cocktail (eBioscience, #00-4980-03; 1:500, Thermo Fisher Scientific). As positive control, cells were treated with Cell Stimulation Cocktail (eBioscience, #00-4970-93). Cells were incubated for 4 h at 37°C and then surface antigens were stained as described above. Afterward, a master mix of desired antibodies in 25 µL FACS buffer containing 0.05% saponin (Sigma, 47036) against intracellular antigens of interest were added and incubated for 90 min at 4°C (IFNγ: PE-Cy7, clone XMG1.2; IL-2: PE, clone JES6-5H4; TNFα: APC, clone MP6-XT22; all Biolegend. all 1:200). Next, cells were washed twice with FACS buffer, resuspended in 100 µL and analyzed by flow cytometry.

**Quantitative proteomics**

Three TMT 6-plex runs were carried out to monitor the changes in liver protein abundance during the entire course of infection. The first run included biological replicates from day 2 and day 8 after infection along with the uninfected controls. The second run included replicate samples of uninfected controls, day 30 and day 60 after infection. To account for the effect of aging, the third run included uninfected controls at day 0 and day 123, along with infected samples from day 123 (all in biological replicates). Identical uninfected controls (day 0) were included in all three TMT 6-plex runs as an internal control to monitor reproducibility between the runs. Liver tissues were homogenized (TissueLyser II, QIAGEN) in 1.5 mL 50 mM HEPES buffer, pH 8.5 supplemented with 2% sodium dodecyl sulfate (SDS). The protein concentrations were determined by the bicinchoninic acid assay (BCA, Pierce Biotechnology, Thermo Scientific, IL). Further processing was adapted from a filter-aided sample preparation (FASP) method previously described (Manza et al., 2005; Wisniewski et al., 2009). For each sample, 100 µg of the liver tissue lysate was reduced with 100 µM dithiothreitol (DTT) and transferred into VIVACON 500 filter unit (Vivaproducts, Littleton, MA). SDS-containing buffer was removed from the sample by centrifugation and exchanged with 8 M urea in 100 mM Tris-HCl buffer. Proteins were alkylated with 50 mM iodoacetamide and washed with 50 mM triethyl ammonium bicarbonate (TEAB). Finally, porcine trypsin (Promega, Madison, WI) was used for protein digestion in an enzyme to protein ratio of 1:100 w/w.
For relative protein quantitation, six samples from each run were separately derivatized with TMT 6-plex reagents (ABI, Framingham, MA) according to the instructions provided by the manufacturer. The combination of the TMT 6-plex labels was as follows: (i) Run 1: day 0 uninfected (TMT 126 and 127), day 2 infected (TMT 128 and 129) and day 8 infected (TMT 130 and 131); (ii) Run 2: day 0 uninfected (126 and 127), day 30 infected (128 and 129) and day 60 infected (130 and 131); and (iii) Run 3: day 0 (126 and 127), day 123 uninfected (128 and 129) and day 123 infected (130 and 131).

The TMT-labeled tryptic digests were pooled and concentrated by solid phase extraction (SPE) (MacroSpin columns 30-300 μg capacity, The Nest Group, Southborough, MA, USA). Samples were treated with 20 mM ammonium formate prior to injection onto a Phenomenex column (150 × 2.0 mm Gemini®-NX-C18 3 μm 110 Å, Phenomenex, Torrance, CA, USA) in an Agilent 1200 series HPLC (Agilent Biotechnologies, Palo Alto, CA) with UV detection at 214 nm. HPLC solvent A consisted of 20 mM ammonium formate, pH 10 in 5% acetonitrile. Peptides were separated at flow rate of 100 μL/min and eluted from the column with a non-linear gradient ranging from 0 to 100% solvent B (20 mM ammonium formate, pH 10 in 90% acetonitrile). Seventy-two time-based fractions were collected, acidified, and pooled into 50 HPLC vials based on the UV trace. After removal of organic solvent in a vacuum centrifuge, samples were reconstituted to 10 μL with 5% formic acid (Bennett et al., 2011). Individual fractions were further analyzed at pH 2.4 by Agilent 1200 nano-HPLC system (Agilent Biotechnologies, Palo Alto, CA) coupled to a hybrid LTQ Orbitrap Velos mass spectrometer (ThermoFisher Scientific, Waltham, MA). Data were acquired utilizing the Xcalibur software version 2.1. Briefly, single fractions were loaded onto a trap column (Zorbax 300SB-C18 5 μm, 5 × 0.3 mm, Agilent Biotechnologies, Palo Alto, CA) with a binary pump at a flow rate of 45 μL/min. Solvents for LCMS separation were composed of 0.1% trifluoroacetic acid (TFA) in water (solvent A) and 0.1% TFA in 70% methanol and 20% isopropanol (solvent B). The peptides were eluted by back-flushing from the trap column onto a 16 cm fused silica analytical column with an inner diameter of 50 μm packed with C18 reversed-phase material (ReproSil-Pur 120 C18-AQ, 3 μm, Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). Elution was achieved with a 27 min gradient ranging from 3 to 30% solvent B, followed by a 25 min gradient from 30 to 70% solvent B and, finally, a 7 min gradient from 70 to 100% solvent B at a constant flow rate of 100 nL/min. The analysis was performed in a data-dependent acquisition mode. The 10 most intense ions were isolated and fragmented by high-energy collision-induced dissociation (HCD) for peptide identification and relative quantitation of TMT reporter ions. Dynamic exclusion for selected ions was 60 s and a single lock mass at m/z 445.120024 (Si(CH3)2O)620 (Olsen et al., 2005) was used for internal mass calibration with the target loss mass abundance of 0%. Maximal ion accumulation time allowed was 500 ms and overfilling of the C-trap was prevented by automatic gain control set to 106 ions for a full FTMS scan and 5 for internal mass calibration with the target loss mass abundance of 0%. Dynamic exclusion for selected ions was 60 s and a single lock mass at m/z 445.120024 (Si(CH3)2O)620 (Olsen et al., 2005) was used for internal mass calibration with the target loss mass abundance of 0%. Maximal ion accumulation time allowed was 500 ms and overfilling of the C-trap was prevented by automatic gain control set to 106 ions for a full FTMS scan and 5 for internal mass calibration with the target loss mass abundance of 0%.

Targeted LC-MS based metabolite measurements

Tissue samples were homogenized using a Precellys 24 tissue homogenizer (Precellys CK14 lysing kit, Bertin). Per mg tissue, 3 μL of 80% (v/v) methanol were added. 10 μL of homogenized tissue sample or serum were mixed with 10 μL of an isotopically labeled internal standard mixture in a hydrophobic 96 well filter plate. Aliquots of 300 μL of methanol were added and mixed for 20 min at 450 rpm. Afterward, the sample extracts were collected by centrifuging the filter plate for 5 min at 500 g. A Vanquish UHPLC system (Thermo Scientific) coupled with an Orbitrap Q Exactive (Thermo Scientific) mass spectrometer was used for the LC-MS analysis. The chromatographic separation was carried out on an ACQUITY UPLC BEH Amide, 1.7 μm, 2.1x100 mm analytical column (Waters) equipped with a VanGuard: BEH C18, 2.1x5mm pre-column (Waters). The column was maintained at a temperature of 40 °C and 2 μL sample were injected per run. The mobile phase A was 0.15% formic acid (v/v) in water and mobile phase B was 0.15% formic acid (v/v) in 85% acetonitrile (v/v) with 10 mM ammonium formate. The gradient elution with a flow rate 0.4 mL/min was performed with a total analysis time of 17 min. The Orbitrap Q Exactive (Thermo Scientific) mass spectrometer was operated in an electrospray ionization positive mode, spray voltage 3.5 kV, aux gas heater temperature 400 °C, capillary temperature 350 °C, aux gas flow rate 12. The metabolites of interest were analyzed using a full MS scan mode, scan range m/z 50 to 400, resolution 35000, AGC target 16, maximum IT 50ms. The Trace Finder 4.1 software (Thermo Scientific) was used for the data processing. Seven-point linear calibration curves with internal standardization and 1/x weighing was constructed for the quantification of metabolites.

Metabolite measurements using the AbsoluteIDQ p180 Kit (Biocrates Life Science AG) were performed as described previously (St. John-Williams et al., 2017). In brief, per mg of tissue, 6 μL ethanol/phosphate buffer (85:15 v/v ethanol/10 mM phosphate buffer) were added and the tissue was homogenized (TissueLyser II, QIAGEN). Samples were centrifuged at 5,000 g for 5 min at 4 °C and the supernatants were transferred to a fresh tube and used for analyses. For serum samples, blood was collected from mice in blood collection tubes and centrifuged at 12,000 g for 5 min to obtain sera. The serum was transferred into a fresh tube and stored at –80 °C until analyses. The samples were analyzed on a Xevo TQ-MS (Waters) mass spectrometer using an Acquity UHPLC (Waters) system, operated with MassLynx V4.1 (Waters). Samples and additional blanks, calibration standards measurements, quality controls, and analyses were prepared according to the user manual.

QUANTIFICATION AND STATISTICAL ANALYSIS

RNA-seq data processing

RNA quality and integrity were assessed via an Experion RNA HighSense chip (Biorad). The library for RNA-seq was prepared using the TruSeq RNA sample preparation kit v2 (Illumina) according to the manufacturer’s protocol. Quality control analysis was performed on all samples of the cDNA library by Experion DNA Analysis chip (Biorad) and Qubit Fluorometric quantitation (Life Tech).
Single cell RNA-seq processing
We performed single-cell RNA-sequencing on a 10X Genomics Chromium Single Cell Controller with the Chromium Single Cell 3’ V3 Kit following the manufacturer’s instructions. Sequencing was performed on an Illumina HiSeq 3000 instrument in 2x75bp paired-end mode. We used the Cell Ranger (v3.0.2) 10X Genomics software to demultiplex the raw sequencing data and align them to the mouse GRCm38 reference genome. We proceeded with the analysis of the UMI counts using the R Bioconductor package Seurat v3.1.0 (Stuart et al., 2019). The two samples, uninfected and 2 days post infection, were merged and processed together. Cells with more than 30% mitochondrial content were discarded. Mitochondrial genes, as well as genes that were not detected in more than 1 cell were discarded. We used markers for Kupffer (Clec4f, Csfr1r, C1qc, C1qa, C1qb), endothelial (Kdr, Eglf7, Igfbp7, Aqp1) and hepatocyte (Apoa1, Apob, Pck1, G6pc, Ttr) cells for cell identification (Halpern et al., 2017). In order to focus on hepatocytes, we kept only those cells that had a summed expression of hepatocyte markers greater than both the summed expression of Kupffer as well as endothelial cells markers. We also eliminated cells that had less than 0.5% of Alb reads. The normalization of the UMI counts was performed with the SCTransform from the Seurat Package, with the regression variable on the condition (uninfected and 2 dpi) (Hafemeister and Satija, 2019). We further ran PCA on the normalized counts and the 3,000 most variable genes. Based on the Jack Straw method we selected the first 20 principal components explaining most of the variability and proceeded with a UMAP low-dimensional projection. Differential analysis between the 2 conditions was performed using the FindMarkers function in Seurat, based on the Wilcoxon test with a Bonferroni correction. Genes were considered as differentially expressed if they had an absolute average log2 fold-change greater than 0.2 and an adjusted p value smaller than 0.05.

Principal component analysis
Principal component analysis (PCA) was performed on the gene set with a minimum average expression level across conditions of 5 FPKM. Only the 10% most variable (computed on the coefficient of variance) genes were considered for the PCA analysis.

Hierarchical clustering
Hierarchical clustering of different gene sets FPKM or CPM expression as well as metabolite abundance values were performed using a Pearson distance measure with an average clustering method. A k-means ++ (z-norm) clustering approach using expresscluster software v1.3 (http://cbdm.hms.harvard.edu/LabMembersPages/SD.html) was performed on the union of differentially modulated genes or metabolites.

Interaction model
For the interaction model (2x2 factorial design) of naive versus LCMV-infected Ifnar1+/+ and Ifnar1−/−, we quantified gene expression as the number of reads covering each gene. The gene expression on the mouse Ensembl e87 transcripts was quantified from the previously TopHat2 mapped reads with featureCounts (Liao et al., 2014). Raw read counts were normalized with the voom (Law et al., 2014) function of the limma package (Smyth, 2004). Normalized expression values, reported as log2 counts per million (CPM), were then processed through limma’s empirical Bayes models. We implemented limma’s interaction model as a two (Ifnar1+/+, Ifnar1−/−) by two (naive, LCMV-infected) factorial design. Genes differentially modulated in the interaction model have been selected based on a minimum log2 CPM of 0, an adjusted p value ≤ 0.05 and a minimum log2 fold-change absolute value of 1 (heatmap) or 0.6 (circos plot).

Enrichments and pathway analyses
Enrichment analyses on the union of differential modulated entities (transcripts and/or proteins) specific clusters were done in Cyto-scape CleaveGO (Bindea et al., 2009) v2.3.3, based on GO (Biological Processes, Molecular Functions, Immune System Process), InterPro, KEGG, Reactome and Wiki Pathways. Terms were called enriched based on a maximum p value of 0.05 and a minimum of 2% gene overlap. GO Term Fusion and grouping was applied. Enriched groups where further ranked according to the group Bonferroni step-down adjusted p value.

For metabolic pathway enrichment analyses, we took the union of differentially expressed genes (expression ≥ 1 FPKM, absolute log2 fold-change ≥ 0.7, adjusted p value ≤ 0.05) and proteins (absolute log2 fold-change ≥ 0.25 and adjusted ratio p value < 0.05 and sample p value < 0.05) across all time points. We extracted metabolism-associated genes from KEGG (Kanehisa and Goto, 2000) metabolic pathways database. Only the pathways with q value of enrichment < 0.05 were considered. The enriched pathways are
represented as a circos plot (Krzywinski et al., 2009), with the width of each ribbon in a given category representing the percentage of genes at each time point among all genes leading to enrichments in the respective category. The color gradient (from lighter to darker) represents the percentage of pathways in each category that were found as enriched at a specific time point.

Mass spectrometry data processing
The acquired raw MS data files were processed with msconvert (ProteoWizard Library v2.1.2708) and converted into MASCOT generic format (mgf) files. Peptides were identified by searching the resultant peak lists against the SwissProt mouse database version v2013.01_20130110 (24615 sequences; 1428050 residues) with the search engines MASCOT (v2.3.02, MatrixScience, London, UK) and Phenyx (v2.5.14, GeneBio, Geneva, Switzerland). Submission to the search engines was done via a Perl script that performs an initial search with relatively broad mass tolerances (MASCOT only) on both the precursor and fragment ions (±10 ppm and ±0.6 Da, respectively). High-confidence peptide identifications were used to recalibrate all precursors and fragment ion masses prior to a second search with narrower mass tolerances (±4 ppm and ±0.025 Da). Trypsin was chosen as cleavage specificity with the maximum of 1 miscleavage site allowed. Carbamidomethyl cysteine, N-terminal and lysine-modified TMT 6-plex were set as fixed modifications, whereas oxidized methionine was set as a variable modification.

To validate the proteins, MASCOT and Phenyx output files were processed by internally developed parsers. Proteins with ≥2 unique peptides above a score T1, or with a single peptide above a score T2, were selected as unambiguous identifications. Additional peptides for these validated proteins with score > T3 were also accepted. For MASCOT and Phenyx, T1, T2, and T3 peptide scores were equal to 16, 40, 10 and 5.5, 9.5, 3.5, respectively (P value < 10−5). The validated proteins retrieved by the two algorithms were then assessed, any spectral conflicts discarded, and grouped according to shared peptides. A false positive detection rate (FDR) of <1% and <1% was determined for proteins and peptides, respectively, by applying the same procedure against a reversed database.

The log2 fold-change cutoffs for differential protein modulation were determined based on pairwise comparisons of protein abundances between the two replicates of uninfected control samples across the 3 independent runs. The 2.5% and 97.5% quartiles of the inter-replica pairwise log2 fold-change were computed. Based on the quartile values, we have set the cutoff at 0.25 and −0.25 for up- and down-modulated proteins, respectively. Additional to the log2 fold-change, statistical significance of observed changes was calculated by Isobar software (Breitwieser et al., 2011). Adjusted P value ratio as well as the P value samples as calculated by Isobar were asked to be less than 0.05.

Targeted LC-MS based metabolite quantification
Metabolite measurements using the AbsoluteIDQ p180 Kit (Biocrates Life Science AG) were validated with the supplied software MetDiQ, Version 5-4-8-DB100-Boron-2607 (Biocrates Life Sciences). All metabolite abundances inferior to the limit of detection (LOD) were replaced with a value equal to half the LOD. We eliminated all metabolites that did not have an average abundance superior to LOD in at least one condition. Modulation of metabolites was assessed through a t test between conditions. The cutoffs for the modulation were obtained based on all the inter-replica pairwise comparisons of wild-type uninfected samples. The 2.5% and 97.5% quartiles of these inter-replica log fold-change were used to define the cutoffs. The cutoffs were −0.44 and 0.65 for the whole liver dynamics serum metabolite measurements. For serum measurements of Ifnar1+/− and Ifnar1−/− mice at 1.5 days post infection, based on the same approach, we have set the cutoffs at −0.73 and 0.4. Significance was inferred based on a p value inferior to 0.05. For the interaction model (2x2 factorial design) of naive versus LCMV-infected Ifnar1+/− and Ifnr1+/−, we implemented limma’s interaction model as a two (Ifnar1+/−, Ifnr1−/−) by two (naive, LCMV-infected) factorial design. Significantly modulated metabolites in the interaction model were identified by an absolute log2 fold change of 0.7 and a p value inferior to 0.05.

Metabolite tracing quantification
Metabolite tracing data were processed using the TraceFinder 4.1 software (Thermo Scientific).

Immunohistochemistry quantification
Images were photographed using an Olympus BX 53 microscope, and were quantified using HistoQuest TM software (TissueGnostics GmbH, Vienna, Austria).

Statistical information
Data are presented as arithmetic mean ± SEM. Statistical significances were calculated using a Student’s t test when comparing two groups or using two-way ANOVA with Bonferroni correction when comparing longitudinal changes. * p < 0.05 ** p < 0.01 *** p < 0.001.

DATA AND CODE AVAILABILITY
Proteomic data (PRIDE: PXD011122) and transcriptomic data (GEO: GSE123688, which includes GEO: GSE118703, GSE123684, GSE118819 and GSE137082 and PRIDE: PXD011122) are deposited in the PRIDE and GEO databases, respectively.